T2Bmeet
Q2 T2Bmeet @ SF 2026
Register for T2Bmeet @ San Francisco
In addition to networking, Mirum and T2B are partnering with Life Science Cares for an optional giveback activity benefiting Breakthrough SF. Join us!
T2B Pro or T2B Student members: get your promo code here
Look for an automated confirmation email and calendar invite within one business day from our event management platform, Luma. If you do not receive it, check your spam folder or contact us at [email protected].
About our T2Bmeet @ SF host
Mirum Pharmaceuticals
Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum focuses on rare liver and rare genetic diseases, where it has built deep expertise and
Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), zilurgisertib, an ALK2 inhibitor under regulatory review with the FDA for fibrodysplasia ossificans progressiva (FOP), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS).
Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at www.mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagr